Dr. Tracey Evans on Chemotherapy for the Elderly Patient

Video

Tracey Evans, MD, Associate Professor of Clinical Medicine University of Pennsylvania Health System, discusses how to determine which patients will benefit from chemotherapy.

Tracey Evans, MD, Associate Professor of Clinical Medicine University of Pennsylvania Health System, discusses how to determine which patients will benefit from chemotherapy.

The elderly, who are defined as those aged 65 or older, have historically not been considered good candidates for chemotherapy, Evans says. Because of this, they are often denied chemotherapy or given more gentle chemotherapy regimen.

Evans says more recent studies have shown that physiologic age is more important than chronological age. While elderly patients tend to experience more toxicities with chemotherapy​, they see the same survival benefit from platinum-based doublet chemotherapy as non-elderly patients.

Related Videos
Núria Agustí Garcia, MD
Erin Frances Cobain, MD
Kian-Huat Lim, MD, PhD
Joaquim Bellmunt, MD, PhD
Stephen V. Liu, MD
Olalekan O. Oluwole, MBBS, MD, associate professor, medicine, hematology/oncology, Vanderbilt Institute for Infection, Immunology and Inflammation, Vanderbilt University Medical Center
Andrew P. Jallouk, BS, MD, PhD, assistant professor, Vanderbilt University
Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Debu Tripathy, MD